Overweight Patients with Pituitary Tumors Exhibit Reduced Growth Hormone Secretion
Background
Non-functioning pituitary tumors (NFPTs) are common benign brain tumors that do not produce excess hormones, but can still impact pituitary function by compressing surrounding tissue. Growth hormone (GH) is crucial for metabolism, body composition, and overall well-being. While obesity is known to affect GH secretion in the general population, the specific association between overweight or obesity and GH secretion in patients already diagnosed with NFPTs has been less clear, especially regarding its clinical implications. This study aimed to quantify the relationship between body weight status and GH secretion in patients with NFPTs.
Results
The study revealed a significant inverse association between increasing BMI and peak growth hormone secretion in patients with NFPTs. Overweight patients (BMI 25-29.9 kg/m²) showed a 38% lower mean peak GH response compared to normal-weight individuals (p<0.01). Patients classified as obese (BMI ≥30 kg/m²) exhibited an even more pronounced reduction, with their mean peak GH response being 55% lower than that of normal-weight controls (p<0.001). Furthermore, the prevalence of diagnosed growth hormone deficiency (GHD) was significantly higher in heavier individuals: 62% of obese patients and 41% of overweight patients met the criteria for GHD, compared to only 20% of normal-weight patients (p<0.001).
Why It Matters
This research highlights a crucial, often overlooked, factor influencing growth hormone status in patients with non-functioning pituitary tumors: their body weight. The finding that overweight and obesity significantly exacerbate GH deficiency in this vulnerable population suggests that managing body weight could be a critical component of comprehensive care for NFPT patients. This understanding could lead to improved diagnostic strategies for GHD and potentially guide personalized treatment approaches, including GH replacement therapy, in overweight or obese individuals with NFPTs. Future prospective studies and potentially clinical trials are warranted to explore the impact of weight loss interventions on GH secretion in this patient group.